Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AD/PD 2024 | Promising FONLISA test for ultrasensitive detection of plasma NfL in Alzheimer’s disease

Madison Honey, PhD candidate, Amsterdam University Medical Centre, Amsterdam, Netherlands, describes the promising neurofilament light chain (NfL) detection capacity of a prototype point-of-care Fiber Optic Nanogold-linked Immunosorbent Assay (FONLISA). NfL has demonstrated diagnostic and prognostic value as a biomarker for acute or chronic neuro-axonal damage. Aiming to develop a rapid and cost-effective detection method, the study tested a FONLISA-based method, which employs fiber optic particle plasmon resonance (FOPPR) technology, for the real-time detection of analytes. The FONLISA test was able to differentiate between plasma samples from controls and those from patients with Alzheimer’s disease (AD), showing significantly higher NfL levels in the AD group. These results correlated strongly with those of a more expensive single-molecule array assay. Given machine portability, cost-effectiveness, and evidenced reproducibility and reliability, this technique holds promise for point-of-care applications. This interview took place at the AD/PD™ 2024 congress in Lisbon, Portugal.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.